BRKR Bruker Corporation
USHealthcareAs of 2026-07-10 16:00
Why BRKR matters now
Bruker Corporation (BRKR) is a US stock in Healthcare. The latest InvestLog snapshot shows $60.06 with -0.86% on the session and $9.14B in market capitalization; recent performance reads 1-month +34.37% and YTD +21.48%.
The latest financial table shown here is Q1 2026, with revenue of $823.4M, net income of $14.4M, and EPS of $0.02. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.6%.
The latest indexable market news headline is "Bruker Gains 50.3% in a Year: What's Driving the Rally?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $47.50; recent insider activity includes Munch Mark filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.56
P/S
2.52
EV/EBITDA
33.86
DCF Value
$36.91
FCF Yield
0.6%
Div Yield
0.3%
Margins & Returns
Gross Margin
45.6%
Operating Margin
5.9%
Net Margin
-0.3%
ROE
-0.5%
ROA
-0.2%
ROIC
-2.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $823.4M | $14.4M | $0.02 |
| Q4 2025 | $977.2M | $26.0M | $0.10 |
| FY 2025 | $3.44B | $-8.6M | $-0.15 |
| Q3 2025 | $860.5M | $-59.6M | $-0.41 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$47.67
Target (Median)
$47.50
Target Range
$35.00 - $58.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.30
Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.